Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 49 min ago
Peer-reviewedCC BYCancers

Advanced Therapies for the Management of Immune Checkpoint Inhibitor-Induced Colitis

  • Cosimo Simone Matichecchia1
  • Fabrizio Fanizzi1
  • Alessandra Zilli1
  • Roberto Ferrara2
  • Sara Oresti2
  • Luca Albarello3
  • Mariangela Allocca1
  • Laurent Peyrin-Biroulet4
  • Silvio Danese1
  • Ferdinando D’Amico1
4 affiliations
  1. 1Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, 20132 Milan, Italy; (C.S.M.); (F.F.); (A.Z.); (M.A.); (S.D.)
  2. 2Department of Medical Oncology, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, 20132 Milan, Italy; (R.F.); (S.O.)
  3. 3Pathology Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy;
  4. 4Northwestern Medicine, Digestive Health Institute, Chicago, IL 60611, USA;
Read full textPDFCite

Related

  1. Case Report: Immune checkpoint inhibitor–induced hypophysitis presenting as acute paralytic ileus mimicking mechanical bowel obstruction in a patient affected by advanced non-small cell lung cancer
    Alice Baggi, Anna Adriani, Luca Carlofrancesco Ammoni +6
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  2. Economic evaluation of six immune checkpoint inhibitor-based first-line therapies for advanced squamous non-small-cell lung cancer: a cost-effectiveness analysis based on network meta-analysis
    Zijian Qiu, Guodong Wang, Ying Lou +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefPMC
  3. Case Series: Severe cholangitis as an immune checkpoint inhibitor induced adverse event in four cases: management and treatment options including tocilizumab and ursodeoxycholic acid
    Darina Kohoutova, Joshua Shur, Monica Terlizzo +17
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  4. 993 Optimizing management of immune checkpoint inhibitor-mediated toxicity in cancer patients
    Pratik Shah, Mark Butler, Neha Puttagunta +5
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYOncologyDOAJ
  5. Marked Response to Nivolumab Plus Ipilimumab After the Failure of Two Prior Immune Checkpoint Inhibitor–Based Regimens Including CTLA-4 Blockade in Advanced Hepatocellular Carcinoma
    Shinichiro Minami, Wataru Sato, Kenjiro Yamamoto +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedGeneral medicineJ-STAGE

Cite

BibTeXRIS
BibTeX
@article{matichecchia2026advanced,
  title = {{Advanced Therapies for the Management of Immune Checkpoint Inhibitor-Induced Colitis}},
  author = {Cosimo Simone Matichecchia and Fabrizio Fanizzi and Alessandra Zilli and Roberto Ferrara and Sara Oresti and Luca Albarello and Mariangela Allocca and Laurent Peyrin-Biroulet and Silvio Danese and Ferdinando D’Amico},
  journal = {Cancers},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13664336},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Advanced Therapies for the Management of Immune Checkpoint Inhibitor-Induced Colitis
AU  - Cosimo Simone Matichecchia
AU  - Fabrizio Fanizzi
AU  - Alessandra Zilli
AU  - Roberto Ferrara
AU  - Sara Oresti
AU  - Luca Albarello
AU  - Mariangela Allocca
AU  - Laurent Peyrin-Biroulet
AU  - Silvio Danese
AU  - Ferdinando D’Amico
PY  - 2026
DA  - 2026/09/24
JO  - Cancers
UR  - https://europepmc.org/article/PMC/PMC13664336
SN  - 2072-6694
ER  -